Dyslipoproteinemia in pediatric systemic lupus erythematosus

Norman Todd Ilowite, P. Samuel, E. Ginzler, M. S. Jacobson

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Patients with systemic lupus erythematosus are at increased risk for premature atherosclerosis. We examined one possible etiologic factor, dyslipoproteinemia, both before and after corticosteroid therapy. We identified 2 distinct patterns of dyslipoproteinemia. One is attributable to active disease; the other is attributable, in part, to corticosteroid therapy. The dyslipoprotinemia of active disease consists of depressed high density lipoprotein cholesterol and apoprotein A-I with elevated very low density lipoprotein cholesterol and triglyceride, while the dyslipoproteinemia after corticosteroid therapy consists of increased total cholesterol, very low density lipoprotein cholesterol, and triglyceride. The possible pathophysiologic mechanisms responsible for these patterns, as well as the possible roles in premature atherosclerosis seen in systemic lupus erythematosus patients, are discussed.

Original languageEnglish (US)
Pages (from-to)859-863
Number of pages5
JournalArthritis and Rheumatism
Volume31
Issue number7
StatePublished - 1988

Fingerprint

Dyslipidemias
Systemic Lupus Erythematosus
VLDL Cholesterol
Adrenal Cortex Hormones
Pediatrics
Atherosclerosis
Apoproteins
HDL Cholesterol
Therapeutics
Cholesterol
very low density lipoprotein triglyceride

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Ilowite, N. T., Samuel, P., Ginzler, E., & Jacobson, M. S. (1988). Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis and Rheumatism, 31(7), 859-863.

Dyslipoproteinemia in pediatric systemic lupus erythematosus. / Ilowite, Norman Todd; Samuel, P.; Ginzler, E.; Jacobson, M. S.

In: Arthritis and Rheumatism, Vol. 31, No. 7, 1988, p. 859-863.

Research output: Contribution to journalArticle

Ilowite, NT, Samuel, P, Ginzler, E & Jacobson, MS 1988, 'Dyslipoproteinemia in pediatric systemic lupus erythematosus', Arthritis and Rheumatism, vol. 31, no. 7, pp. 859-863.
Ilowite, Norman Todd ; Samuel, P. ; Ginzler, E. ; Jacobson, M. S. / Dyslipoproteinemia in pediatric systemic lupus erythematosus. In: Arthritis and Rheumatism. 1988 ; Vol. 31, No. 7. pp. 859-863.
@article{57c3d10b1a3e433a9396deeb5f423c7a,
title = "Dyslipoproteinemia in pediatric systemic lupus erythematosus",
abstract = "Patients with systemic lupus erythematosus are at increased risk for premature atherosclerosis. We examined one possible etiologic factor, dyslipoproteinemia, both before and after corticosteroid therapy. We identified 2 distinct patterns of dyslipoproteinemia. One is attributable to active disease; the other is attributable, in part, to corticosteroid therapy. The dyslipoprotinemia of active disease consists of depressed high density lipoprotein cholesterol and apoprotein A-I with elevated very low density lipoprotein cholesterol and triglyceride, while the dyslipoproteinemia after corticosteroid therapy consists of increased total cholesterol, very low density lipoprotein cholesterol, and triglyceride. The possible pathophysiologic mechanisms responsible for these patterns, as well as the possible roles in premature atherosclerosis seen in systemic lupus erythematosus patients, are discussed.",
author = "Ilowite, {Norman Todd} and P. Samuel and E. Ginzler and Jacobson, {M. S.}",
year = "1988",
language = "English (US)",
volume = "31",
pages = "859--863",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Dyslipoproteinemia in pediatric systemic lupus erythematosus

AU - Ilowite, Norman Todd

AU - Samuel, P.

AU - Ginzler, E.

AU - Jacobson, M. S.

PY - 1988

Y1 - 1988

N2 - Patients with systemic lupus erythematosus are at increased risk for premature atherosclerosis. We examined one possible etiologic factor, dyslipoproteinemia, both before and after corticosteroid therapy. We identified 2 distinct patterns of dyslipoproteinemia. One is attributable to active disease; the other is attributable, in part, to corticosteroid therapy. The dyslipoprotinemia of active disease consists of depressed high density lipoprotein cholesterol and apoprotein A-I with elevated very low density lipoprotein cholesterol and triglyceride, while the dyslipoproteinemia after corticosteroid therapy consists of increased total cholesterol, very low density lipoprotein cholesterol, and triglyceride. The possible pathophysiologic mechanisms responsible for these patterns, as well as the possible roles in premature atherosclerosis seen in systemic lupus erythematosus patients, are discussed.

AB - Patients with systemic lupus erythematosus are at increased risk for premature atherosclerosis. We examined one possible etiologic factor, dyslipoproteinemia, both before and after corticosteroid therapy. We identified 2 distinct patterns of dyslipoproteinemia. One is attributable to active disease; the other is attributable, in part, to corticosteroid therapy. The dyslipoprotinemia of active disease consists of depressed high density lipoprotein cholesterol and apoprotein A-I with elevated very low density lipoprotein cholesterol and triglyceride, while the dyslipoproteinemia after corticosteroid therapy consists of increased total cholesterol, very low density lipoprotein cholesterol, and triglyceride. The possible pathophysiologic mechanisms responsible for these patterns, as well as the possible roles in premature atherosclerosis seen in systemic lupus erythematosus patients, are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0023792957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023792957&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 859

EP - 863

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 7

ER -